Radiolabeling of rituximab with 188Re and 99mTc using the tricarbonyl technology

Nuclear Medicine and Biology

Volumn 38, Issue 1, 2011, Pages 19-28

  Dias, Carla Roberta ^a   Jeger, Simone ^b   Osso, João Alberto ^a   Müller, Cristina ^b   De Pasquale, Christine ^b   Hohn, Alexander ^b   Waibel, Robert ^b   Schibli, Roger ^b,c  

^a INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

^b ETH Zurich   (Switzerland)

^c ETH ZURICH   (Switzerland)

Author keywords

188Re; 99mTc; Radioimmunoconjugate; Rituximab; Tricarbonyl core

Indexed keywords

CD20 ANTIGEN; CYSTEINE; HISTIDINE; MERCAPTOETHANOL; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; RITUXIMAB RE 188; RITUXIMAB TC 99M; THIOL GROUP; TRICARBOXYLIC ACID; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; RADIOISOTOPE; RHENIUM; TECHNETIUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CHELATION; CONTROLLED STUDY; DISULFIDE BOND; DRUG DISTRIBUTION; DRUG SCREENING; DRUG STABILITY; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; NONHUMAN; RADIOIMMUNOLOGY; RAJI CELL; REDUCTION; ANIMAL; AUTORADIOGRAPHY; BLOOD; CHEMISTRY; IMMUNOLOGY; METABOLISM; METHODOLOGY; MOUSE; NONHODGKIN LYMPHOMA; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; AUTORADIOGRAPHY; CELL LINE, TUMOR; CYSTEINE; DRUG STABILITY; FEMALE; HISTIDINE; HUMANS; ISOTOPE LABELING; LYMPHOMA, NON-HODGKIN; MICE; ORGANOTECHNETIUM COMPOUNDS; RADIOISOTOPES; RHENIUM;

EID: 78650981859     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.05.010     Document Type: Article

References (35)

1. Hamoudeh M., Kamleh M.A., Diab R., Fessi H. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv Drug Deliv Rev 2008, 60:1329-1346.
2. Hernandez M.C., Knox S.J. Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. Int J Rad Oncol Biol Phys 2004, 59(5):1274-1287.
3. Cheson B.D. Radioimmunotherapy of non-Hodgkin lymphomas. Blood 2003, 101(2):391-398.
4. Conti P.S. Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin): the role of the nuclear medicine physician. Semin Nucl Med 2004, 34:2-3.
5. Macklis R.M. Radioimmunotherapy as a therapeutic option for non-Hodgkin's lymphoma. Semin Radiat Oncol 2007, 17:176-183.
6. Kosmas C., Stamatopoulos K., Stavroyianni N., Tsavaris N., Papadaki T. Anti-CD20-based therapy of B cell lymphoma: state of the art. Leukemia 2002, 16:2004-2015.
7. Eisenberg R., Looney R.J. The therapeutic potential of anti-CD20 What do B-cells do? Clin Immunol 2005, 117:207-213.
8. Liebenguth P., Temple S.V. Radioimmunotherapy for non-Hodgkin's lymphoma. Semin Oncol Nursing 2006, 22(4):257-266.
9. Rao A.V., Schmader K. Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults. Am J Geriatric Pharmacoth 2007, 5(3):247-262.
10. Maloney D.G., Grillo-López A.J., White C.A., Bodkin D., Schilder R.J., Neidhart J.A., et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195.
11. Stern M., Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Critical Rev Oncol Hematol 2005, 54:11-29.
12. Müller C., Schubiger P.A., Schibli R. Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors. Nucl Med Biol 2007, 34(6):595-601.
13. Ferro-Flores G., Torres-García E., García-Pedroza L., Arteaga de Murphy C., Pedraza-López M., Garnica-Garza H. An efficient, reproducible and fast preparation of 188Re-anti-CD20 for the treatment of non-Hodgkin's lymphoma. Nucl Med Comm 2005, 26:793-799.
14. Stopar T.G., Mlinaric-Rascan I., Fettich J., Hojker S., Mather S.J. 99mTc-Rituximab radiolabelled by photo-activation: a new non-Hodgkin's lymphoma imaging agent. Eur J Nucl Med Mol Imaging 2006, 33(1):53-59.
15. Torres-García E., Ferro-Flores G., Arteaga de Murphy C., Correa-González L., Pichardo-Romero P.A. Biokinetics and dosimetry of 188Re-anti-CD20 in patients with non-Hodgkin's lymphoma: preliminary experience. Arch Med Res 2008, 39(1):100-109.
16. Raposinho P.D., Correia J.D.G., Alves S., Botelho M.F., Santos A.C., Santos I. A 99mTc(CO)3-labeled pyrazolyl-[alpha]-melanocyte-stimulating hormone analog conjugate for melanoma targeting. Nucl Med Biol 2008, 35(1):91-99.
17. Schibli R., Schwarzbach R., Alberto R., Ortner K., Schmalle H., Dumas C., et al. Steps toward high specific activity labeling of biomolecules for therapeutic application: preparation of precursor [188Re(H2O)3(CO)3]+ and synthesis of tailor-made bifunctional ligand systems. Bioconjugate Chem 2002, 13:750-756.
18. Deyev S.M., Waibel R., Lebedenko E.N., Schubiger A.P., Plückthun A. Design of multivalent complexes using the barnase-barstar module. Nat Biotechnol 2003, 21(12):1486-1492.
19. Willuda J., Kubetzko S., Waibel R., Schubiger P.A., Zangemeister-Wittke U., Plückthun A. Tumor targeting of mono-, di-, and tetravalent anti-p185 (HER-2) miniantibodies multimerized by self-associating peptides. J Biol Chem 2001, 276(17):14385-14392.
20. Waibel R., Alberto R., Willuda J., Finnern R., Schibli R., Stichelberger A., et al. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat Biotechnol 1999, 17:897-901.
21. Chen K.T., Lee T.W., Lo J.M. In vivo examination of 188Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer. Nucl Med Biol 2009, 36:355-361.
22. Lindmo T., Boven E., Cuttitta F., Fedorko J., Bunn P.A. Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984, 72(1):77-89.
23. Liu S. Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv Drug Del Rev 2008, 60(12):1347-1370.
24. Alberto R., Schibli R., Waibel R., Abram U., Schubiger A.P. Basic aqueous chemistry of [M(OH2)3(CO)3]+ (M=Re, Tc) directed towards radiopharmaceutical application. Coord Chem Rev 1999, 192:901-919.
25. Amann A., Decristoforo C., Ott I., Wenger M., Bader D., Alberto R., et al. Surfactant protein B labelled with [99mTc(CO)3(H2O)3]+ retains biological activity in vitro. Nucl Med Biol 2001, 28(3):243-250.
26. The Drug Bank database: http://www.drugbank.ca/drugs/DB00073.
27. Du J., Wang H., Zhong C., Peng B., Zhang M., Li B., et al. Structural basis for recognition of CD20 by therapeutic antibody rituximab. J Biol Chem 2007, 282(20):15073-15080.
28. DeLano W.L., Ultsch M.H., de Vos A.M., Wells J.A. Convergent solutions to binding at a protein-protein interface. Science 2000, 287(5456):1279-1283.
29. Egli A., Alberto R., Tannatoli L., Schibli R., Abram U., Schaffland A., et al. Organometallic 99mTc-Aquaion labels peptide to an unprecedented high specific activity. J Nucl Med 1999, 40:1913-1917.
30. Eckelman W.C., Steigman J. Direct labeling with 99mTc. Nucl Med Biol 1991, 18:3-7.
31. Salfeld J.G. Isotype selection in antibody engineering. Nat Biotech 2007, 25:1369-1372.
32. Subbiah K., Hamlin D.K., Pagel J.M., Wilbur D.S., Meyer D.L., Axworthy D.B., et al. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J Nucl Med 2003, 44:437-445.
33. DeNardo S.J., Kroger L.A., DeNardo G.L. A new era for radiolabeled antibodies in cancer? Curr Opin Immunol 1999, 11(5):563-569.
34. Holliger P., Hudson P.J. Engineering antibody fragments and the rise of single domains. Nat Biotech 2005, 23:1126-1136.
35. Jalilian A.R., Mirsadeghi L., Haji-Hosseini R., Khorrami A. Preparation, quality control and biodistribution studies of [67Ga]-DOTA-anti-CD20. Radiochim Acta 2008, 96:167-174.